This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Comments on Cost Analysis of Risperidone Versus Olanzapine

Harpreet S. Duggal, MD, DPM; Gaurav Gandotra, MD

Published: June 1, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Taylor et al.1 report a naturalistic nonrandomized retrospective study comparing inpatient costs for risperidone with olanzapine. The disadvantages inherent to a nonrandomized study (with no blinding) are not the only shortcomings of the study, and therefore, its results should be interpreted with caution.

First, the study reflects a viewpoint from a hospital’s perspective as opposed to a societal perspective. A consequence of this narrow viewpoint of studying only inpatients is that it is not known whether patients discharged early differ from those discharged late in their utilization of outpatient resources and subsequent course of illness.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 65

Quick Links: